Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI.
Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active Surveillance
University of California, San Francisco urologist Dr. Cooperberg discusses the use of biomarkers in the prostate cancer active surveillance. Following the presentation, radiation oncologist Dr. Robert Den of Thomas Jefferson University and urologist Dr. Sanoj Punnen of the University of Miami share their perspectives on the topic in a question-and-answer session.
Introducing Decipher’s Next-Generation Prostate Biopsy Test Report
Decipher's expanded prostate cancer genomics test report makes it easier to understand and discuss your patient's personalized results.
The Role of Genomics in Deciding Between Active Surveillance and Treatment
Ashley E. Ross, MD, PhD, an associate professor of urology at Northwestern University, discusses the use of genomics in selecting the most appropriate treatment for newly diagnosed prostate cancer patients.
Decipher and Intermediate Risk Prostate Cancer
Daniel Spratt, MD, Professor of Radiation Oncology at University of Michigan School of Medicine, discusses the use of genomics in the management of men with newly diagnosed intermediate risk prostate cancer.
Decipher Prostate Case Review: Impact of Genomics in Decision Making for Intermediate Risk Disease
Featuring Dr. Ashley Ross of Northwestern University and Dr. Phuoc Tran of Johns Hopkins University
A Genomic Guide to Inform Multidisciplinary Management of Post-RP Radiation Therapy
Featuring Dr. Edouard Trabulsi, MD and Dr. Robert Den, MD from Thomas Jefferson University
Intermediate Risk Prostate Cancer
Felix Feng, MD
Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses the intermediate risk prostate cancer stratification challenge and the utility of genomics in this setting
Molecular Subtyping in Prostate Cancer
Felix Feng, MD
Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses genomic subtyping in prostate cancer and how it is being investigated in prospective trials
Applying a Clinical Genomic Nomogram for ADT Decisions in Intermediate Risk Prostate Cancer
Featuring Jeff Michalski, MD, MBA, FASTRO
Decipher Prostate: A Different Approach to Prostate Cancer … We’re Here to Help
Decipher Biosciences has developed a new tool to help with prostate cancer management. A diagnostic test that provides meaningful and independent data to assess the underlying biology and risk of a man's cancer. A test that, when used in conjunction with clinical information, can provide clarity and confidence in determining the best treatment plan.
Using Decipher Testing to Inform ADT Decisions in Intermediate Risk Prostate Cancer
Overview of the ADT dilemma, current clinical data, and how Decipher testing can help improve decision-making
Decipher in CHAARTED
Dr. Anis Hamid, MBBS
Gene expression profiling of metastatic prostate cancer in the CHAARTED trial reveals predictors of chemotherapy benefit with Dr. Anid Hamid, MBBS, Oncology research fellow at Dana-Farber Cancer Institute